Rasna Therapeutics Book Value Per Share vs. EBITDA
| RASP Stock | USD 0 0.00 0.00% |
For Rasna Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Rasna Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Rasna Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Rasna Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Rasna Therapeutics over time as well as its relative position and ranking within its peers.
Rasna |
Rasna Therapeutics EBITDA vs. Book Value Per Share Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Rasna Therapeutics's current stock value. Our valuation model uses many indicators to compare Rasna Therapeutics value to that of its competitors to determine the firm's financial worth. Rasna Therapeutics is rated below average in book value per share category among its peers. It is currently regarded as top stock in ebitda category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Rasna Therapeutics' earnings, one of the primary drivers of an investment's value.Rasna EBITDA vs. Book Value Per Share
Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.
Rasna Therapeutics |
| = | (0.01) X |
The naive approach to look at Book Value per Share is to compare it to current stock price. If Book Value per Share is higher than the currently traded stock price, the company can be considered undervalued. However, investors must be aware that conventional calculation of Book Value does not include intangible assets such as goodwill, intellectual property, trademarks or brands and may not be an appropriate measure for many firms.
EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Rasna Therapeutics |
| = | 254.41 K |
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
Rasna EBITDA Comparison
Rasna Therapeutics is currently under evaluation in ebitda category among its peers.
Rasna Therapeutics Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Rasna Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Rasna Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Rasna Therapeutics' change in net profit over the period of time. It can combine multiple indicators of Rasna Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Rasna Therapeutics, Inc., a leukemia-focused biotechnology company, engages in developing therapeutics for the treatment of acute myeloid leukemia and other forms of leukemia and lymphoma. Rasna Therapeutics, Inc. was founded in 2013 and is headquartered in New York, New York. Rasna Therapeutics operates under Biotechnology classification in the United States and is traded on OTC Exchange.
Rasna Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Rasna Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Rasna Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Rasna Therapeutics' important profitability drivers and their relationship over time.
Learn to be your own money manager
Our tools can tell you how much better you can do entering a position in Rasna Therapeutics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Portfolio Holdings Now
Portfolio HoldingsCheck your current holdings and cash postion to detemine if your portfolio needs rebalancing |
| All Next | Launch Module |
Use Investing Themes to Complement your Rasna Therapeutics position
In addition to having Rasna Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Transportation Thematic Idea Now
Transportation
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Transportation theme has 61 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Transportation Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Rasna Pink Sheet Analysis
When running Rasna Therapeutics' price analysis, check to measure Rasna Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Rasna Therapeutics is operating at the current time. Most of Rasna Therapeutics' value examination focuses on studying past and present price action to predict the probability of Rasna Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Rasna Therapeutics' price. Additionally, you may evaluate how the addition of Rasna Therapeutics to your portfolios can decrease your overall portfolio volatility.